SK145896A3 - Medicaments containing therapeutically effective quantity of antigen peptid of human mbp and ifn-beta - Google Patents

Medicaments containing therapeutically effective quantity of antigen peptid of human mbp and ifn-beta Download PDF

Info

Publication number
SK145896A3
SK145896A3 SK1458-96A SK145896A SK145896A3 SK 145896 A3 SK145896 A3 SK 145896A3 SK 145896 A SK145896 A SK 145896A SK 145896 A3 SK145896 A3 SK 145896A3
Authority
SK
Slovakia
Prior art keywords
peptide
amino acid
mbp
acid residues
ifn
Prior art date
Application number
SK1458-96A
Other languages
English (en)
Slovak (sk)
Inventor
Di-Hwei Hsu
Dawn Smilek
Jia Dong Shi
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of SK145896A3 publication Critical patent/SK145896A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK1458-96A 1994-05-10 1995-05-04 Medicaments containing therapeutically effective quantity of antigen peptid of human mbp and ifn-beta SK145896A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24124694A 1994-05-10 1994-05-10
US32822494A 1994-10-25 1994-10-25
PCT/US1995/005605 WO1995030435A2 (fr) 1994-05-10 1995-05-04 Compositions et traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
SK145896A3 true SK145896A3 (en) 1997-05-07

Family

ID=26934122

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1458-96A SK145896A3 (en) 1994-05-10 1995-05-04 Medicaments containing therapeutically effective quantity of antigen peptid of human mbp and ifn-beta

Country Status (11)

Country Link
EP (1) EP0758902A1 (fr)
JP (1) JPH10500109A (fr)
AU (1) AU2470595A (fr)
CA (1) CA2189990A1 (fr)
CZ (1) CZ329596A3 (fr)
HU (1) HUT76099A (fr)
IL (1) IL113661A0 (fr)
PL (1) PL317197A1 (fr)
SI (1) SI9520059A (fr)
SK (1) SK145896A3 (fr)
WO (1) WO1995030435A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2203629A1 (fr) * 1994-10-25 1996-05-02 Dawn Smilek Compositions et traitement pour la sclerose en plaques
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
CA2250361A1 (fr) * 1996-03-28 1997-10-02 Barbara Wallner Peptides de la glycoproteine d'oligodendrocyte de myeline et leurs utilisations
CA2263730A1 (fr) * 1996-08-15 1998-02-19 Agrivax Incorporated Administration d'antigenes tolerogeniques via des plantes comestibles ou des produits derives de plantes
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
EP1311542B1 (fr) * 2000-08-21 2008-07-16 Apitope Technology (Bristol) Limited Peptides tolerogéniques
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
BR0308923A (pt) 2002-03-27 2005-01-04 Aegera Therapeutics Inc OligÈmeros de nucleobase de iap anti-sentido e empregos destes
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021222A1 (fr) * 1992-04-09 1993-10-28 Autoimmune, Inc. Repression de la proliferation des lymphocytes t grâce a l'utilisation de fragments peptidiques provenant de la proteine de base de la myeline
IL106720A (en) * 1992-08-17 1998-10-30 Autoimmune Inc The use of antigen bystander in the preparation of compositions for the treatment of neurologically related diseases in mammals and such compositions

Also Published As

Publication number Publication date
EP0758902A1 (fr) 1997-02-26
WO1995030435A3 (fr) 1995-12-07
CA2189990A1 (fr) 1995-11-16
AU2470595A (en) 1995-11-29
WO1995030435A2 (fr) 1995-11-16
PL317197A1 (en) 1997-03-17
JPH10500109A (ja) 1998-01-06
CZ329596A3 (en) 1997-05-14
HU9603116D0 (en) 1997-01-28
IL113661A0 (en) 1995-08-31
SI9520059A (en) 1997-08-31
HUT76099A (en) 1997-06-30

Similar Documents

Publication Publication Date Title
EP0498658B1 (fr) Composition pour induire une anergy humorale vis à vis d'un immunogène
JP2635444B2 (ja) 自己抗体の経口投与による自己免疫性疾患の治療
US8454967B2 (en) Compositions and methods for modulating the immune system
SK145896A3 (en) Medicaments containing therapeutically effective quantity of antigen peptid of human mbp and ifn-beta
Wraith et al. Cross-reactive antigen recognition by an encephalitogenic T cell receptor. Implications for T cell biology and autoimmunity.
EA003944B1 (ru) Способы лечения диабета с помощью пептидных аналогов инсулина
CA2203629A1 (fr) Compositions et traitement pour la sclerose en plaques
JP2607751B2 (ja) 自己免疫性ブドウ膜網膜炎の治療予防薬
Miller et al. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases
Li et al. T cell epitope selection: dominance may be determined by both affinity for major histocompatibility complex and stoichiometry of epitope
Selaa Specific vaccines against autoimmune diseases
KR100333148B1 (ko) 당뇨질환예방제및치료제로서사용되는Vα14Jα281을함유하는가용성T-세포수용체α쇄및유도체
US6265374B1 (en) Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
ES2222625T3 (es) Peptido t y peptidos asociados destinados al tratamiento de la inflamacion incluyendo la esclerosis multiple.
US11167005B2 (en) Peptides for treating Sjogren's syndrome
Skurkovich et al. A disturbance of interferon synthesis with the hyperproduction of unusual kinds of interferon can trigger autoimmune disease and play a pathogenetic role in AIDS: the removal of these interferons can be therapeutic
JPH07508521A (ja) 重症筋無力症処置用合成ペプチド
SK102199A3 (en) Peptides comprising a t-cell epitope specific to collagen ii, their use and pharmaceutical compositions containing such peptides
Skurkovich et al. A disturbance of interferon synthesis with the hyperproduction of unusual kinds of interferon can trigger autoimmune disease and play a pathogenetic role in AIDS: the removal of these interferons can be therapeutic
WO1999037315A1 (fr) Derives chimiques d'autoantigenes et de peptides suppresseurs d'auto-immunisation, et preparations pharmaceutiques les contenant
WO2013020914A1 (fr) Peptides peg-conjugués
CN114641304A (zh) 改良的疫苗制剂
JPH10120591A (ja) 免疫寛容誘導剤
CN1079908A (zh) 组胺衍生物及其用作免疫调节剂的方法